Am J Transplant, Volume 5, Suppl 3 Archives - Page 109 of 170 - ATC Abstracts

2015 American Transplant Congress
Associations Between Sirolimus Use and Outcomes After Liver Transplant for Hepatocellular Carcinoma
E. Yanik,¹ S. Chinnakotla,² A. Israni,^2,3 J. Snyder,^2,3 S. Gustafson,³ E. Engels.¹
¹Natl. Cancer Inst., Bethesda, MD; ²U. of Minnesota, Minneapolis, MN; ³Sci. Reg. of Transplant Recipients, Minneapolis, MN.
A growing fraction of U.S. liver transplants are being done for the indication of hepatocellular carcinoma (HCC). HCC recurrence after transplant remains a major concern…
2015 American Transplant Congress
Age-Specific Graft Failure Rates in Pediatric Liver Transplant Recipients
B. Foster,¹ M. Dahhou,¹ X. Zhang,¹ V. Dharnidharka,² J. Conway,³ V. Ng.⁴
¹Pediatrics, Research Institute of the McGill Univ. Health Centre, Montreal, QC, Canada; ²Pediatrics, Washington Univ., St. Louis, MO, Central African Republic; ³Pediatrics, Stollery Children's Hospital, Edmonton, AB, Canada; ⁴Transplant and Regenerative Medicine Center, Hospital for Sick Children, Toronto, ON, Canada.
Graft failure risk peaks during emerging adulthood (18-25 y) in kidney transplant recipients. The association between age and graft failure risk in liver transplant recipients…
2015 American Transplant Congress
High Incidence of Masked Hypertension in Pediatric Recipients of Stem Cell Transplantation
A. Melk,¹ D. Thurn-Valsassina,¹ B. Schmidt,² R. Beier.³
¹Pediatric Nephrology, Hannover Medical School, Hannover, Germany; ²Nephrology, Hannover Medical School, Hannover, Germany; ³Pediatric Hematology, Hannover Medical School, Hannover, Germany.
Purpose: Different from recipients of a solid organ transplant, stem cell transplantation (SCT) recipients do not receive long term immunosuppressive treatment that may cause renal…
2015 American Transplant Congress
Current Dialysis, Previous Kidney Transplant, and Autoimmune Disease Increase Risk for Abnormal Pap Smear in Women Undergoing Kidney Transplant Evaluation
K. Chaung,¹ Y. Zheng,¹ A. Martella,² J. Stoecker,¹ D. Cote,¹ J. Augustine,² E. Sanchez,² V. Humphreville,² J. Ammori,² K. Woodside.²
¹Case Western Reserve University School of Medicine, Cleveland, OH; ²University Hospitals, Cleveland, OH.
The USPSTF recommends Pap smears every three years for women 21-65, with optional combination Pap smear and HPV testing every five years for women 30-65.…
2015 American Transplant Congress
Preferences for Policy Options for Deceased Organ Donation for Transplantation: A Discrete Choice Experiment
K. Howard,¹ S. Jan,² J. Rose,³ G. Wong,^1,4 J. Craig,^1,4 M. Irving,¹ A. Tong,^1,4 S. Chadban,^1,5 R. Allen,⁵ A. Cass.⁶
¹The University of Sydney, Sydney, Australia; ²The George Institute for Global Health, Sydney, Australia; ³Institute for Choice, University of South Australia, North Sydney, Australia; ⁴Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Australia; ⁵Department of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, Australia; ⁶Menzies School of Health Research, Darwin, Australia.
Background: Despite broad public support for organ donation, there is a chronic shortage of deceased donor organs. We sought to identify features of an organ…
2015 American Transplant Congress
African American Race Is an Independent Risk Factor for Cytomegalovirus Infection in Renal Transplant Recipients on Low-Dose Valganciclovir Prophylaxis
S. Patel, S. Kuten, J. Loucks-DeVos, R. Knight, A. Gaber.
Houston Methodist Hospital, Houston, TX.
Safe and effective use of low-dose (450 mg/day) valganciclovir (VGC) for cytomegalovirus (CMV) prophylaxis in renal transplant recipients (RTRs) has been reported. However, it is…
2015 American Transplant Congress
Safety and Efficacy of Pegylated Interferon and Ribavirin for Chronic Hepatitis C Following Renal Transplantation
G. Chen, L. Zhu, S. Chen, X. Wang, Z. Lin.
Institute of Organ Transplantation, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Objective We sought to investigate the safety and efficacy of pegylated Interferon (PEG-IFN) and ribavirin for chronic hepatitis C (HCV) following renal transplantation.Methods Ten adult…
2015 American Transplant Congress
Do CMS Oversight and the Systems Improvement Agreement Really Change Institutional Behavior?
C. Hoopes.
Center for Transplantation and Organ Failure, University of kentucky, Lexington, KY.
In 2010 the pulmonary transplant program at the University of Kentucky entered a Systems Improvement Agreement (SIA) with CMS as a consequence of poor performance…
2015 American Transplant Congress
A Novel, Blocking Anti-CD40 Monoclonal Antibody Prolongs Non-Human Primate Renal Allograft Survival in the Absence of B-Cell Depletion Or Thromboembolic Events
J. Rush,¹ G. Wieczorek,¹ M. Audet,² M. Schneider,¹ P. Espie,³ L. Roth,¹ C. Heusser,¹ C. Bruns,¹ D. Patel,¹ F. Cordoba.¹
¹Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, Basel, Switzerland; ²Hôpital de Hautepierre, Strasbourg, France; ³Drug Metabolism and Pharmacokinetics, Novartis Institutes for Biomedical Research, Basel, Switzerland.
Background. CD40-CD154 pathway blockade prolongs renal allograft survival in non-human primates (NHPs). However, antibodies targeting CD154 were associated with an increased incidence of thromboembolic complications…
2015 American Transplant Congress
Vaccination to Prevent the High Herpes Zoster Incidence After Renal Transplantation
M. Kho,¹ W. Weimar,¹ D. Boveé,¹ M. Boer-Verschragen,¹ A. van der Eijk,² N. van Besouw.¹
¹Internal Medicine - Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, Netherlands; ²Viroscience, Erasmus Medical Center, Rotterdam, Netherlands.
Introduction: Herpes zoster (HZ) is the clinical manifestation of varicella zoster virus (VZV) reactivation and occurs more frequently in people with a suppressed immune system.…